Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Inovio Pharmaceuticals, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Inovio Pharmaceuticals, Inc. is not a good value stock. Inovio Pharmaceuticals, Inc. is not a good growth stock. Inovio Pharmaceuticals, Inc. is not very popular among insiders. Inovio Pharmaceuticals, Inc. is a mediocre stock to choose.

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery,...

News

Inovio Pharmaceuticals (NASDAQ:INO) and Inari Medical (NASDAQ:NARI) Head to Head Contrast

Zolmax Inari Medical (NASDAQ:NARI - Get Free Report) and Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) are both medical companies, but which is the better business? We will compare the two...\n more…

Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $44.00

Zolmax Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat...\n more…

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of "Moderate Buy" by Analysts

Ticker Report Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat reports. Two...\n more…

Inovio Pharmaceuticals (NASDAQ:INO) PT Lowered to $33.00 at Oppenheimer

Ticker Report Inovio Pharmaceuticals (NASDAQ:INO - Free Report) had its target price trimmed by Oppenheimer from $40.00 to $33.00 in a report released on Monday, Benzinga reports. The firm currently has an...\n more…

Inovio Pharmaceuticals (NASDAQ:INO) PT Lowered to $8.00 at Royal Bank of Canada

Ticker Report Inovio Pharmaceuticals (NASDAQ:INO - Free Report) had its target price cut by Royal Bank of Canada from $11.00 to $8.00 in a report published on Friday morning, Benzinga reports. They currently have...\n more…

Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $56.75

Zolmax Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are presently covering the stock, Marketbeat.com...\n more…